Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.52 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.35 |
| ▸ | SELE | P16581 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.34 |
| ▸ | CTRC | Q99895 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1851165 | 1.00 | CYP2A6 (0.52) | CYP2A6SLC9A1PTPN2ICAM1SELE | |
| SCHEMBL31589064 | 0.83 | SLC9A1 (0.43) | CYP2A6SLC9A1MAOAMAOBCA2 | |
| SCHEMBL2089632 | 0.81 | SLC9A1 (0.45) | CYP2A6SLC9A1MAOAMAOBCA2 | |
| SCHEMBL717886 | 0.79 | CYP2A6 (0.53) | CYP2A6SLC9A1ICAM1SELESLC22A12 | |
| SCHEMBL27293788 | 0.79 | CYP2A6 (0.53) | CYP2A6ICAM1SELEMAOAMAOB | |
| SCHEMBL29058591 | 0.78 | CYP2A6 (0.52) | CYP2A6SLC9A1ICAM1SELEMAOB | |
| SCHEMBL27575951 | 0.75 | ALDH1A1 (0.50) | SLC9A1MAOAMAOBCA2HDAC3 | |
| SCHEMBL28205208 | 0.74 | SLC9A1 (0.47) | SLC9A1MAOAMAOBCA2HDAC3 | |
| SCHEMBL1745259 | 0.74 | SLC9A1 (0.50) | CYP2A6SLC9A1PTPN2ICAM1SELE | |
| SCHEMBL5555026 | 0.73 | ICAM1 (0.50) | CYP2A6PTPN2ICAM1SELESLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743174-A1 | MODULATORS OF CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | Aconcagua Bio, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20250179055-A1 | Substituted 2-(pyrrolidine-3-yl)acetic acid derivative, preparation method and use thereof | INNOVSTONE THERAPEUTICS LIMITED (CN) | 2025-06-05 | — | — | US | disclosed |
| WO-2025103442-A1 | SUBSTITUTED 2-(PYRROLIDIN-3-YL)ACETIC ACID DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翊石医药科技有限公司 | 2025-05-22 | — | — | WO | disclosed |
| US-20250042916-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ACONCAGUA BIO, INC. | 2025-02-06 | — | — | US | disclosed |
| WO-2025015268-A1 | MODULATORS OF CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | ACONCAGUA BIO, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179055-A1 | Substituted 2-(pyrrolidine-3-yl)acetic acid derivative, preparation method and use thereof | PCSK9, LPL, LYPLA1 | CYP2A6 1329/4885SLC9A1 1728/4885PTPN2 1012/4885 |
| US-20250042916-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | IAPP, GIPR, GPR119 | CYP2A6 3708/4885SLC9A1 2258/4885PTPN2 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.